Hostname: page-component-669899f699-7tmb6 Total loading time: 0 Render date: 2025-04-27T05:25:13.901Z Has data issue: false hasContentIssue false
  • English
  • Français

New Medications for Epilepsy

Published online by Cambridge University Press:  07 November 2014

John F. Kerrigan
Get access Rights & Permissions [Opens in a new window]

Abstract

The last 4 years have seen a rapid burst of development of medications used to treat epileptic seizures. While none of these medications has replaced the “standards” in the field, they collectively offer additional treatment options for patients, particularly for those with difficult-to-control seizures. As experience with these novel medications grows, each will occupy its own niche in the treatment strategy for patients with epilepsy.

Type
Feature Articles
Information
CNS Spectrums , Volume 2 , Issue 7: Imitators of Epilepsy: Treatment Options , August 1997 , pp. 43 - 58
Copyright
Copyright © Cambridge University Press 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1.Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med. 1993;328:29–33.CrossRefGoogle Scholar
2.Faught, E, Sachdeo, RC, Remier, MP, et al.Felbamate monotherapy for partial onset seizures: an active-control trial. Neurology. 1993;43:688–692.CrossRefGoogle Scholar
3.Leppik, IE. Felbamate. Epilepsia. 1995;36(suppl 2):66–72.CrossRefGoogle ScholarPubMed
4.Sofia, RD. Felbamate: mechanisms in action. In: Levy, RH, Mattson, RH, Meldrum, BS, eds. Antiepileptic Drugs. 4th ed. New York, NY: Raven Press; 1995:791–797.Google Scholar
5.Pennell, PB, Ogaily, MS, Macdonald, RL. Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology. 1995;45:456–460.CrossRefGoogle Scholar
6.O'Neil, MG, Perdun, CS, Wilson, MB, McGown, ST, Patel, S. Felbamate-associated fatal acute hepatic necrosis. Neurology. 1996;46:1457–1459.CrossRefGoogle ScholarPubMed
7.American Epilepsy Society. Wallace Laboratories. 1994.Google Scholar
8.Beydoun, A, Uthman, BM, Sackellares, JC. Gabapentin: pharmacokinetics, efficacy, and safety. Clin Neuropharmacol. 1995;18:469–481.CrossRefGoogle ScholarPubMed
9.Leiderman, DB. Gabapentin as add-on therapy for refractory partial epilepsy: results of five placebo-controlled trials. Epilepsia. 1994;35(suppl 5):74–76.CrossRefGoogle ScholarPubMed
10.Anhut, H, Ashman, P, Feuerstein, TJ, Sauermann, W, Saunders, M, Schmidt, B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. Epilepsia. 1994;35:795–801.CrossRefGoogle ScholarPubMed
11.Khurana, DS, Riviello, J, Helmers, S, Holmes, G, Anderson, J, Mikati, MA. Efficacy of gabapentin therapy in children with refractory partial seizures. J Pediatr. 1996;128:829–833.CrossRefGoogle ScholarPubMed
12.Ramsey, RE. Gabapentin: toxicity. In: Levy, RH, Mattson, RH, Meldrum, BS. eds. Antiepileptic Drugs. 4th ed. New York, NY: Raven Press; 1995:857–860.Google Scholar
13.Lee, DO, Steingard, RJ, Cesena, M, Helmers, SL, Riviello, JJ, Mikati, MA. Behavioral side effects of gabapentin in children. Epilepsia. 1996;37:87–90.CrossRefGoogle ScholarPubMed
14.Messenheimer, JA. Lamotrigine. Epilepsia. 1995;36(suppl 2):87–94.CrossRefGoogle ScholarPubMed
15.Besag, FMC, Wallace, SJ, Dulac, O, Alving, J, Spencer, SC, Hosking, G. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr. 1995;127:991–997.CrossRefGoogle ScholarPubMed
16.Timmings, PL, Richens, A. Lamotrigine as an add-on drug in the management of Lennox- Gastaut syndrome. Eur Neurol. 1992;32:305–307.CrossRefGoogle ScholarPubMed
17.Richens, A. Lamotrigine: toxicity. In Levy, RH, Mattson, RH, Meldrum, BS, eds. Antiepileptic Drugs. 4th ed. New York, NY: Raven Press, 1995:897–902.Google Scholar
18.Dooley, J, Camfield, P, Gordon, K. Camfield, C, Wirrell, E, Smith, E. Lamotrigine-induced rash in children. Neurology. 1996;46:240–242.CrossRefGoogle ScholarPubMed
19.Ben-Menachem, E. Topiramate. In: Levy, RH, Mattson, RH, Meldrum, BS, eds. Antiepileptic Drugs. 4th ed. New York, NY: Raven Press; 1995:1063–1070.Google Scholar
20.Shorvon, SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia. 1996;37(suppl 2):18–22.CrossRefGoogle ScholarPubMed
21.Ben-Menachem, E, Henriksen, O, Dam, M, et al.Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia. 1996;37:539–543.CrossRefGoogle ScholarPubMed
22.Tassinari, CA, Michelucci, R, Chauvel, P, et al.Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia. 1996;37:763–768.CrossRefGoogle ScholarPubMed
23.Sachdeo, RC, Reife, RA, Lim, P, Pledger, G. Topiramate monotherapy for partial onset seizures. Epilepsia. 1997;38:294–300.CrossRefGoogle ScholarPubMed
24.Browne, TR, Kugler, AR, Eldon, MA. Pharmacology and pharmacokinetics of fosphenytoin. Neurol. 1996;46(suppl 1):3–7.Google ScholarPubMed
25.Wilder, BJ, Campbell, K, Ramsay, RE, et alSafety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery. Arch Neorol. 1996;53:764–768.CrossRefGoogle ScholarPubMed
26.Pellock, JM. Fosphenytoin use in children. Neurology. 1996;46(suppl 1):14–16.CrossRefGoogle ScholarPubMed
27.Ramsay, RE, DeToledo, J. Intravenous administration of fosphenytoin: options for the management of seizures. Neurology. 1996;46(suppl 1):17–19.CrossRefGoogle ScholarPubMed
28.Kerrigan, JF, Fisher, RS. Recurrent generalized and partial seizures. In: Johnson, RT, Griffin, JW, eds. Current Therapy in Neurologic Disease. 5th ed. St. Louis, Mo: Mosby Year Book; 1996:47–55.Google Scholar
29.Nitsche, V, Mascher, H. The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers. Epilepsia. 1982;23:153–162.CrossRefGoogle ScholarPubMed
30.Devinsky, O, Leppik, I, Willmore, LJ, et al, and the Intravenous Valproate Study Team. Safety of intravenous valproate. Ann Neurol. 1995;38:670–674.CrossRefGoogle ScholarPubMed
31.Rosner, H, Rubin, L, Kestenbaum, A. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain. 1996;12:56–58.CrossRefGoogle ScholarPubMed
32.Ryback, R, Ryback, L. Gabapentin for behavioral dyscontrol. Am J Psychiatry. 1995;152:1399. Letter.Google ScholarPubMed